Results | Latest & Breaking News on Results | Photos, Videos, Breaking Stories and Articles on Results

you are here: Home News

Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
Biocon shares slump 5.5% as net profit takes a dive in Q2
Biocon Q4 PAT may dip 192.8% YoY to Rs 67.1 cr: ICICI Securities
Biocon Q1 PAT seen up 21% YoY to Rs 180.7 cr: ICICI Direct
Biocon Q4 PAT seen up 54.1% YoY to Rs. 203.4 cr: Sharekhan
Biocon Q3 PAT may dip 1.5% YoY to Rs. 199.7 cr: ICICI Direct
Biocon Q4 PAT seen up 35.2% YoY to Rs. 176.2 cr: Kotak
Biocon Q3 PAT seen up 106.5% YoY to Rs. 190 cr: Sharekhan
Biocon Q3 PAT seen up 105.4% YoY to Rs. 188.7 cr: ICICI Direct
Biocon confident of meeting $200-million revenue guidance target for biologics segment
Biocon Q2 PAT seen up 38.2% YoY to Rs. 123 cr: Sharekhan
Biocon Q2 PAT seen up 105.9% YoY to Rs. 141.6 cr: ICICI Direct
Biocon Q1 PAT seen up 70.8% YoY to Rs. 138.9 cr: Kotak
Biologics biz a large value unlocking opportunity; see revival from Q4: Biocon
Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl
Optimistic about entry into generics market; hoping for better returns in H2: Biocon
Biocon Q2 PAT may dip 27.2% YoY to Rs. 107.1 cr: Kotak
Have buy rating on Glenmark Pharma: HDFC Securities
Biocon Q1 profit seen down 32% on weak operational performance
EXCLUSIVE: Biocon open to ‘unlocking value’ in units after 5 years; may look at M&A
Biocon Q4 adjusted profit may grow 32% on strong operational performance
Biocon well-poised to be a frontrunner in biosimilars: MD
Biocon Q3 profit seen up 38% to Rs 142 cr on revenue, EBITDA
Biosimilars to lead growth; generics to be a small part: Biocon
Biocon Q2 profit seen down 55% at Rs 137cr, revenue may grow 19%

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities

Biocon shares slump 5.5% as net profit takes a dive in Q2

Biocon Q4 PAT may dip 192.8% YoY to Rs 67.1 cr: ICICI Securities

Biocon Q1 PAT seen up 21% YoY to Rs 180.7 cr: ICICI Direct

Biocon Q4 PAT seen up 54.1% YoY to Rs. 203.4 cr: Sharekhan

Biocon Q3 PAT may dip 1.5% YoY to Rs. 199.7 cr: ICICI Direct

Biocon Q4 PAT seen up 35.2% YoY to Rs. 176.2 cr: Kotak

Biocon Q3 PAT seen up 106.5% YoY to Rs. 190 cr: Sharekhan

Biocon Q3 PAT seen up 105.4% YoY to Rs. 188.7 cr: ICICI Direct

Biocon confident of meeting $200-million revenue guidance target for biologics segment

Biocon Q2 PAT seen up 38.2% YoY to Rs. 123 cr: Sharekhan

Biocon Q2 PAT seen up 105.9% YoY to Rs. 141.6 cr: ICICI Direct

Biocon Q1 PAT seen up 70.8% YoY to Rs. 138.9 cr: Kotak

Biologics biz a large value unlocking opportunity; see revival from Q4: Biocon

Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl

Optimistic about entry into generics market; hoping for better returns in H2: Biocon

Biocon Q2 PAT may dip 27.2% YoY to Rs. 107.1 cr: Kotak

Have buy rating on Glenmark Pharma: HDFC Securities

Biocon Q1 profit seen down 32% on weak operational performance

EXCLUSIVE: Biocon open to ‘unlocking value’ in units after 5 years; may look at M&A

Biocon Q4 adjusted profit may grow 32% on strong operational performance

Biocon well-poised to be a frontrunner in biosimilars: MD

Biocon Q3 profit seen up 38% to Rs 142 cr on revenue, EBITDA

Biosimilars to lead growth; generics to be a small part: Biocon

Biocon Q2 profit seen down 55% at Rs 137cr, revenue may grow 19%